Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX701 AAV Gene Therapy in Adults With Wilson Disease
NCT04884815Phase 2Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Sep 2021
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 4
01
Overview
A Phase 2 trial of rivunatpagene miziparvovec in Wilson disease (WD), sponsored by Ultragenyx Pharmaceutical Inc.. Started Sep 2021; status: active, not recruiting.
02
Drugs
rivunatpagene miziparvovec
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04884815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884815.